Search

Written by experts in the field, Precision Molecular Pathology of Aggressive B-Cell Lymphomas contains the most recent revisions from the 5th Edition WHO and 2022 International Consensus Classification diagnostic categories and serves as an important resource for trainees, pathologists, haematologist/oncologists, other clinicians involved in lymphoma care and lymphoma researchers. It provides a comprehensive yet concise synthesis of emerging molecular advances that inform patient care and improve understanding of disease mechanisms. In addition, it provides the necessary background to how molecular techniques are performed to enable the reader to better interpret and critically evaluate relevant and emerging data. As part of the Molecular Pathology Library series, this book focuses specifically on aggressive B-cell lymphomas given the increasing relevance of molecular data for diagnosis and treatment of these disorders. This evidence-based text contains 25 chapters and is divided into 5 parts. Part 1 provides a brief history and background of aggressive B-cell lymphomas. Landmark events in their classification and treatment are given in order to place the substantial advances in the field in context. Part 2 reviews molecular pathology methods, including the increasing use of next generation sequencing techniques in clinical practice. Parts 3 and 4 focus on individual subtypes of aggressive B-cell lymphoma, including a summary of the diagnostic criteria and key pathologic and clinical features for each entity. Finally, Part 5 focuses on emerging molecular technologies that may significantly impact clinical practice.

The current medical practice has become more of a team effort rather than an isolated practice. The current evaluation of patients in the daily practice is essentially performed by medical assessment of the patient in question followed by diagnostic imaging, and when needed and possible the evaluation of tissue for diagnosis with its subsequent assessment of biomarkers and other ancillary tools that play an important role in the evaluation and prognosis. The book herein proposed will exactly provide such assessment focused in the thoracic assessment of patients afflicted with any particular disease of the thorax. Expert clinician in pulmonary medicine will provide the state of the art in the evaluation of such patients, which will provide the most important background in the clinical impression and further assessment of these patients. This assessment in most cases is followed by the evaluation of imaging, which provides a highly important information of not only the exact location of the process but also of the nature of whether is localized, infiltrative, diffuse, bilateral, etc., as well as the possible compromise of other adjacent structures. Such information is crucial as imaging and clinical information will provide a working diagnosis, which ultimately will be defined by the pathological assessment. Therefore, in real practice neither one of these subspecialties works alone or in isolation. On the contrary, each one depends on the other for the final diagnosis and proper management of patients with thoracic diseases. Based on such experience is that the current text will provide in the same text of the needed information that a clinician, radiologist or pathologist will need in order to arrive to the best possible conclusion.The scope of this book is unique in its nature as currently, even though there are several text on either one of those specialties, those publication are strictly on the either radiology, medicine or pathology. Our proposed text will bring all those together in a single text and written by experts in their respective field. This book should be of interest to all of those in the practice of thoracic medicine (radiologist, pulmonologist, pathologists) and any one who in the general practice is confronted with the evaluation of these patients.

This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients.This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.

Der Arzneiverordnungs-Report ist seit 1985 eine gemeinsame Publikation von Autoren aus Pharmakologie, Klinik, Praxis, Gesundheitsökonomie und Krankenversicherung. Basis sind die Verordnungsdaten von Arzneimitteln für ambulante Patienten der gesetzlichen Krankenversicherung (GKV). Datenbasis des Jahres 2019 sind 820 Millionen Verordnungen von 179.805 Vertragsärzten und 63.360 Vertragszahnärzten für 73,195 Mio. GKV-Versicherte.Die allgemeine Verordnungs- und Marktentwicklung wird in 5 Kapiteln dargestellt, in denen zusätzlich 31 neue Arzneimittel des Jahres 2019, Biologika und Biosimilars, 10 Jahre AMNOG und europäische Arzneimittelpreise für Biosimilars thematisiert werden. Die speziellen Verordnungsdaten der 3000 meistverordneten Arzneimittel werden in 39 Kapiteln für die führenden Indikationsgruppen evidenzbasiert analysiert.

This book explains the immunology of organ-specific malignancies and discusses novel immunotherapy strategies for their treatment. Since the first, very successful edition of the book was published in 2015, a number of entirely new chapters have been included. The range of cancers considered has accordingly been extended, with coverage of the latest immunotherapy approaches for cancers in different organs. In addition, the original chapters have been updated to document the latest advances in immunotherapy for pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, bone tumors, central nervous tumors, lung cancer, genitourinary tract tumors, and breast cancer, among others. The book is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and bench to bedside immunotherapy. Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors will be of special value to clinical immunologists, hematologists, and oncologists.

This book discusses the unique epidemiology of fungal infections in Asia, illustrating that the situation in these countries is different from that in Western countries in terms of the causative species, natural history and management strategies. Asia, the world's largest continent and home to more than half the global population, has conditions that favor the growth of many fungi, including a number of unique species. Further, socio-economic conditions such as overcrowding, compromised health care facilities and lack of awareness add to the morbidity and mortality due to fungal diseases in this part of the world. Since the majority of Asian countries do not have good diagnostic mycology laboratories, antifungal management is often based on experience. The limited data from Asian countries suggest a very high incidence of fungal infections. This book addresses epidemiology of fungal infections in general and specific populations of Asia, fungal allergy, and diagnosis and management in resource-limited environments. The book is must read for busy clinicians, microbiologists and critical care providers.

Natural killer (NK) cells are important effector cells of innate immune system implicated in many physiological processes including elimination of cancer cells and virus infected cells. NK cells comprise a majority of large granular lymphocytes circulating in peripheral blood with a minority derived from T cell lineage. Even though NK cells were first described more than 40 years ago, it was not until the 1980s and 1990s when immunophenotyping was incorporated into clinical diagnostic methods and resulted in discovery of distinct disorders of large granular lymphocytes and NK cells. Since then, significant progress was made in our better understanding of immunophenotypic and genotypic characteristics, biology, functions as well as disorders of these cells. Most recently, clinical studies using NK-cell based immunotherapy have shown promising results in treatment of some of malignant diseases. Disorders of large granular lymphocytes and NK cells are rare comprising only about 1% of all lymphoid malignancies in western countries. The rarity of these conditions was a main reason that the progress in our understanding of pathogenesis and development of novel therapeutic approaches has been delayed compared to development in more common B cell lymphoid malignancies. The low incidence of these diseases and scarcity of prospective clinical trials also limit the availability of evidence based research literature as well as comprehensive reviews about NK cell disorders. Thus, the editors decided to take on the challenging task and summarize our current knowledge about malignant and benign diseases of large granular lymphocytes in this book based on the best available evidence. The editors selected topics most relevant to clinical practice in order to provide a useful guide for practicing physicians. Chapters describing four disorders (T-cell large granular lymphocytic leukemia, chronic lymphoproliferative disorder of NK cells, extranodal NK cell lymphoma and aggressive NK cell leukemia) incorporated into most recent 2016 revision of classification of lymphoid malignancies are separated into experimental, diagnositc and clinical parts for easier understanding and reading. We are aware of challenges and inherited limitations of any larger project like this one due to a rapid progress especially in the field of genomics, which may not be incorporated in this book before it is published. The editors and contributing authors would like to thank the publisher NOVA for their support.

Im seit 1985 jährlich als Buch erscheinenden Arzneiverordnungs-Report werden die Rezepte für die Patienten der gesetzlichen Krankenversicherung (GKV) mit Methoden der evidenzbasierten Medizin analysiert. Seit dieser Zeit bietet der Report eine unabhängige Informationsmöglichkeit über die verschiedenen Komponenten der Arzneimittelverordnung und trägt damit zur Transparenz des Arzneimittelmarkts, zur Bewertung von Arzneimitteln und zu einer sowohl zweckmäßigen und sicheren evidenzbasierten als auch wirtschaftlichen Arzneitherapie bei.

Im seit 1985 jährlich als Buch erscheinenden Arzneiverordnungs-Report werden die Rezepte für die Patienten der gesetzlichen Krankenversicherung (GKV) mit Methoden der evidenzbasierten Medizin analysiert.Seit dieser Zeit bietet der Report eine unabhängige Informationsmöglichkeit über die verschiedenen Komponenten der Arzneimittelverordnung und trägt damit zur Transparenz des Arzneimittelmarkts, zur Bewertung von Arzneimitteln und zu einer sowohl zweckmäßigen und sicheren evidenzbasierten als auch wirtschaftlichen Arzneitherapie bei.

This revised and updated second edition of Handbook of Hematologic Malignancies continues to be an essential and'go-to'resource for the busy hematologist, hematologic oncologist, hematopathologist, oncology advanced practice provider, oncology nurse, and trainee. Concisely organized, each chapter provides the most current, need-to-know points of diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematological malignancy. Chapters are complete with richly illustrated figures to highlight the hematopathologic characteristics of diseases in addition to helpful tables on differential diagnosis, prognostic scoring systems, molecular profiles, and therapeutic options. A new case-based chapter concludes the handbook with clinical cases designed to test a clinician's knowledge of pathologic diagnosis and clinical presentation of diseases covered in the book. With over twenty new FDA-approved indications since publication of the first edition, including breakthroughs with CAR-T therapy, and other evidence-based treatment options for patients with hematologic disease, this book serves as quick reference to practice changing information on challenging diagnostic dilemmas, frontline and refractory treatment scenarios, and more. The subspecialty field of hematologic oncology is ever-changing and expanding with available treatment options and this second edition keeps the busy clinician abreast of recent findings and their impact on evidence-based treatment and management. Written by experienced clinicians at the world-renowned Moffitt Cancer Center in Tampa, Florida, as well as contributions from leading academicians, hematologists, and oncologists throughout the country, this unique handbook is packed with authoritative knowledge and clinical insight into all known hematologic cancers.Key Features:Includes seven new chapters covering CAR-T and novel therapeutic options including CD19 CAR-T therapy, novel cellular therapies, cytokine release syndrome, cancer associated thrombosis, and moreComprises compact and updated disease-site chapters describing new standards of care and management considerations in bullet point format with key referencesHighlights important diagnostic tools that assist with conducting key differential diagnoses and unveiling answers to diagnostic dilemmasProvides updates of potential practice-changing clinical trials and paradigm shifting treatment considerations in each disease-based chapter

This book will provide an overview of how to manage patients with lymphoma in the format of a series of engaging case studies. Lymphomas are cancers that originate in the lymphatic system. There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. These lymphomas comprise various subtypes with prognosis and treatment depending on the stage and type of the cancer. Lymphoma is a major global health problem; non-Hodgkin lymphoma in particular is the tenth most common type of cancer worldwide. In response to this there have been a number of significant advances in the available treatment options for lymphoma with new breakthrough drugs being approved or registered for approval. In light of this, this case study book will be an extremely timely guide for all hematologists, oncologists, and healthcare professionals wishing to keep up-to-date with these recent developments. The format of this book is also particularly appealing as it offer readers a practical approachto the clinical management of patients with these conditions as suggested by leading physicians from the City of Hope National Medical Center in California, USA in an era of vast therapeutic development.

The leading reference in the field of geriatric care, Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 8th Edition, provides a contemporary, global perspective on topics of importance to today's gerontologists, internal medicine physicians, and family doctors. An increased focus on frailty, along with coverage of key issues in gerontology, disease-specific geriatrics, and complex syndromes specific to the elderly, makes this 8th Edition the reference you'll turn to in order to meet the unique challenges posed by this growing patient population. - Consistent discussions of clinical manifestations, diagnosis, prevention, treatment, and more make reference quick and easy. - More than 250 figures, including algorithms, photographs, and tables, complement the text and help you find what you need on a given condition. - Clinical relevance of the latest scientific findings helps you easily apply the material to everyday practice. - A new chapter on frailty, plus an emphasis on frailty throughout the book, addresses the complex medical and social issues that affect care, and the specific knowledge and skills essential for meeting your patients'complex needs. - New content brings you up to date with information on gerontechnology, emergency and pre-hospital care, HIV and aging, intensive treatment of older adults, telemedicine, the built environment, and transcultural geriatrics. - New editor Professor John Young brings a fresh perspective and unique expertise to this edition.

This book presents original results on the leading edge of cancer research. Chapter One explains unanswered questions of contemporary oncology from the standpoint of karyogamic theory of carcinogenesis. Chapter Two focuses on the molecular players of the human papillomaviruses (HPVs) infection leading to chronic inflammation and cancer. Chapter Three describes Multiple Myeloma (MM), and Monoclonal Gammopathy of Undetermined Significance (MGUS). Chapter Four reviews the role of choline metabolites as second messengers in cellular pathways leading to enhanced cell survival, migration, and proliferation to explore the possibility that in-vivo imaging of choline metabolism can be used to obtain readouts of cell signal transduction in cancer. Chapter Five investigates the possible correlation between anatomic melanoma distribution on the specific back area and lack of sunscreen application. Chapter Six describes the known molecular mechanisms of epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) in malignant neuroblastoma that can help find new directions for future research. Chapter Seven discusses the burdens of childhood cancer survivorship and the consequences of different treatment therapies on the incidence of CVD and explores potential monitoring methods and the need for consistent cardiovascular monitoring of childhood cancer survivors regarding their cardiovascular health. Finally, Chapter Eight considers a model for implementing recommendations pertaining to Lynch syndrome, and also looks at what is happening in the field now to support Lynch syndrome genetic testing and surveillance, and how a deliberative conference can point the way to changes that need to take place to deliver screening to those at risk.

This encyclopedia presents important research on dermatological advances. This six set volume includes discussions on the structure and composition of the dermis layer of the skin; the biosynthesis, functions and health benefits of melanin; the genetics, as well as the geographic variation and disorders, of skin pigmentation; the causes, diagnosis and treatment of alopecia, rosacea, candidiasis, cyanosis, psoriasis, and bullous pemphigoid; new research on skin aging; risk factors, protection practices and health effects of sun exposure; skin cancer prevention; the use of sunscreen; skin cancer prevention guidance for schools and youth; and the epidemiology, management and impact on muscle and joint functions of burns.

This text provides a practical guide for the diagnostic surgical pathologist in evaluating tumors involving the liver. It comprehensively covers the histological findings and key clinical and molecular correlates of liver tumors. The focus is on material that is most relevant to the actual practice of liver pathology including those aspects that are directly relevant to the diagnosis, subtyping and prognostication of hepatic adenomas specimens, including biopsy specimens and surgical resections. The book will teach pathologists how to avoid common diagnostic pitfalls. Each chapter uses or discusses the nomenclature and classification system of liver tumors as per the current WHO classification of liver tumors. Each chapter fully incorporates the most up to date diagnostic methodologies, including immunohistochemistry and molecular methods. Referencing is succinct and references were carefully chosen for their key role as the primary sources of information on a given disease. The text is richly illustrated with beautiful color images that highlight not just the “average” histological findings for a given entity, but also fully illustrate all of the key histological variability. Gross images are also included to highlight important diagnostic features. Tables are used judiciously to present summary information that allows a quick review on how similar entities compare and contrast. In addition, the clinical significance of various diseases will be discussed in a focused fashion that highlights how pathology information is being used to make key clinical management decisions. Each chapter is written by experts in hepatopathology, all from the Mayo Clinic Departments of Pathology.Surgical Pathology of Liver Tumors will be of great utility to surgical pathologists and surgical pathologists in training as well as clinicians involved in the care of patients with liver tumors, particularly hepatologists and oncologists.

With over two hundred types of cancer diagnosed to date, researchers the world over have been forced to rapidly update their understanding of the biology of cancer. In fact, only the study of the basic cellular processes, and how these are altered in cancer cells, can ultimately provide a background for rational therapies. Bringing together the state-of-the-art contributions of international experts, Systems Biology of Cancer proposes an ultimate research goal for the whole scientific community: exploiting systems biology to generate in-depth knowledge based on blueprints that are unique to each type of cancer. Readers are provided with a realistic view of what is known and what is yet to be uncovered on the aberrations in the fundamental biological processes, deregulation of major signaling networks, alterations in major cancers and the strategies for using the scientific knowledge for effective diagnosis, prognosis and drug discovery to improve public health.

Cancer Immunology is intended as an up-to-date, clinically relevant review of cancer immunology and immunotherapy. This volume focuses on the immunopathology and immunotherapy of organ cancers in detail. It clearly explains their immunology and describes novel immunotherapy for specific cancers, including pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, skin cancers, bone and connective tissue tumors, central nervous system tumors, lung cancers, genitourinary tract tumors and breast cancers. In so doing, it builds on the previous two volumes in Cancer Immunology, placing basic knowledge on tumor immunology and immunotherapy into a clinical perspective with the aim of educating clinicians on advances in cancer immunology and the most recent approaches in the immunotherapy of various tumors. This translational, clinically oriented book will be of special value to clinical immunologists, hematologists and oncologists.

Histone deacetylase inhibitors (HDIs) are good anti-cancer targets. Histone acetyltransferases (HATs) and HDIs play opposite roles in the regulation of gene expression via an epigenetic mechanism. HATs catalyze the acetylation of lysine residues in histone tails, facilitating and sustaining gene transcription. HDIs remove the acetyl moieties from the epsilon-amine of lysine residues of histone tails, leading to a more condensed form of chromatin and preventing gene transcription. This book focuses on the use of HDIs for the treatment of lymphoid malignancies; myeloid malignancies; and breast cancer.

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of monoclonal immunoglobulin-secreting plasma cells in the bone marrow (BM). Multiple myeloma is associated with lytic bone lesions, anemia, immunodeficiency and renal impairment. Multiple myeloma accounts for more than 10% of all hematologic malignancies and about 1% of all cancers. Multiple myeloma remains mostly incurable despite conventional intensive high dose chemotherapy followed by hematopoietic stem cell transplant. The costs associated with multiple myeloma are among the highest. This book discusses the diagnosis of multiple myeloma along with the risk factors involved and the treatments that are available.

Cancer is a devastating disease lacking an exact treatment. Recent advances in genetics and biotechnology have provided a deeper understanding of cancer biology, out of which aberrations in oncogenes and tumor suppressor genes have arisen as important etiological factors. Inactivation of tumor suppressor genes is one of the initial cellular changes that ultimately lead to tumor development. Thus increasing knowledge about these genes aids in the development of novel therapeutic applications as well as identification of more effective and rapid molecular markers for early diagnosis and prognostic evaluation. This book provides up-to-date information on the structure, function and roles of the main tumor suppressor genes thus far identified. An important addition to the current literature in the field, this book is intended to help instructors for teaching purposes and researchers in the field of cancer biology as an overview of current knowledge.

Imatinib has brought a revolution in the management of Chronic myelogenous leukemia (CML), a disease which had very limited therapeutic options including allogeneic hematopoietic stem cell transplantation and interferon-alpha 10 years ago. The clinical success of imatinib in CML and gastrointestinal tumors (GIST) has brought up a new paradigm in cancer therapy that has very broad potentials. Imatinib is active against a number of related tyrosine kinases, namely ABL, BCR-ABL, KIT, PFGFR and TEL. Now, as more than a decade has passed since the approval of Imatinib, and after the change of CML from a rapidly fatal disease to a more chronic and manageable disease, we wanted to have a look back at what we know about the drug and its effect on various body systems. Its efficacy, side effects and how to manage its use in non-hematological malignancies is discussed in detail. Gathering all this information in one book will be of immense benefit for healthcare workers including physicians, pharmacists and nurses and this in turn will help them improve the care of their patients. It will also benefit pharmacists who are a source of clinical and pharmacological knowledge. For people undertaking research in the field of hemato-oncology or pharmacology, this will be a useful starting point for reviewing the literature. Imatinib is still being studied in patients in the clinic and laboratory models, and researchers are assessing the use of imatinib in other cancers. The editors have tried to allow information in book chapters to show different aspects and various view points on related issues.

Neoplastic Diseases of the Blood integrates the history, epidemiology, pathology, pathophysiology, and therapeutics of modern neoplastic hematopathology. The book is divided into five major sections, with the first four covering the spectrum of hematologic neoplasia— Chronic Leukemias and Related Disorders, Acute Leukemias, Myeloma and Related Disorders, and Lymphomas. The fifth section covers a variety of topics in supportive care. Now in its fifth edition, this classic and invaluable text brings together a team of internationally renowned experts and offers in-depth coverage of the complex interface between diagnosis and therapy. Chapters feature an accessible and easy-to-read layout and provide updates on the tremendous progress made in the last decade in the understanding of the nature of hematologic malignancies and their treatment. An authoritative and indispensable resource for students, trainees, and clinicians, this fifth edition is sure to distinguish itself as the definitive reference on this topic.

An oncogene is a modified gene or a series of nucleotides that encode a protein and direct the cell to the development of a neoplastic phenotype. Usually, oncogenes are involved in tumor development and increase the possibility that the development of a cell directs towards cancer. In this book, the authors present current research in the study of the classification, mechanisms of activation and role in cancer development of oncogenes. Topics include the role of oncogenes in gynecological pathology; oncomirs as the next frontier of oncogenes affecting cancer etiology and tumor progression; the role of the epidermal growth factor receptor as a therapeutic target in glioblastoma and other malignancies; and tumor suppressors involved in DNA repair and carcinoprevention.

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.

- La 5ª ed. de esta obra de referencia en radiología se presenta en un formato a 2 colores y manteniendo el enfoque claramente clínico de las anteriores ediciones. La obra proporciona un acceso rápido a la información mediante descripciones paso a paso de todas aquellas cuestiones relacionadas con las aplicaciones de Resonancia magnética y Tomografía Computerizada en cada una de las áreas anatómicas, con particular énfasis en la TC multicorte. - La obra utiliza una cuidada selección de imágenes seccionales para así lograr diagnosticar con precisión una amplia gama de condiciones y patologías. Cualquier radiólogo encontrará indispensable este libro a la hora de consultar cuestiones, de todo tipo, relacionadas tanto con la RM como con la TC. - El libro incluye imágenes tanto de RM como de TC para todas las áreas del cuerpo humano. Igualmente cubre procedimientos de intervención para ayudar a aplicar las técnicas guiadas por imagen y presenta todo el material con un enfoque práctico y clínico, incluyendo manifestaciones clínicas de la mayor parte de las condiciones. - La obra muestra al lector cómo interpretar los hallazgos procedentes de las últimas técnicas de vanguardia de TC multicorte, IRM, PET, entre otras. - Incluye la actualización completa de imágenes en todos los capítulos y añade un capítulo nuevo sobre intervenciones guiadas y otros cinco capítulos inéditos sobre trasplante de hígado, pelvis del hombre, pelvis de la mujer, evaluación de las vías aéreas y contraste nefrológico. - Quinta edición de esta obra de enfoque clínico que proporciona un acceso rápido a todas aquellas cuestiones relacionadas con las aplicaciones de RM y TC en las áreas anatómicas con particular énfasis en la TC multicorte. - Utiliza una cuidada selección de imágenes seccionales para lograr diagnosticar con precisión una amplia gama de condiciones y patologías. Cualquier radiólogo encontrará indispensable este libro a la hora de consultar cuestiones, de todo tipo, relacionadas tanto con la RM como con la TC. - Incluye la actualización completa de imágenes en todos los capítulos. - Añade un capítulo nuevo sobre: intervenciones guiadas y otros cinco capítulos inéditos sobre trasplante de hígado, pelvis del hombre, pelvis de la mujer, evaluación de las vías aéreas y contraste nefrológico.

La pathologie ORL souvent peu connue des radiologues est difficile à interpréter. La radiographie standard ayant presque complètement disparu, seules les techniques d'imagerie en coupe, réputées plus complexes, sont utilisées. IRM et scanner sont en effet indispensables au diagnostic de la pathologie inflammatoire (sinusites) ou tumorale (tumeurs du larynx, du pharynx...). Ils constituent désormais des examens de première intention et sont également le complément indispensable de tout bilan d'extension dans le cadre d'une investigation oncologique. L'ouvrage composé de 3 parties : massif facial - région cervicale et VADS - os tempral et angle pontocérébelleux, réalise un bilan complet de l'imagerie des différentes pathologies. Richement illustré, il présente pour chaque partie, les rappels anatomiques, les techniques d'exploration et les bilans radiologiques par pathologie.Le seul ouvrage complet pour les radiologues et les ORL - Le massif facial, la région cervical et VADS, os tempral et l'angle pontocérébelleux avec pour chacun : ▪ Des rappels anatomiques. ▪ Les techniques d'exploration. ▪ Les bilans radiologiques par pathologie. - 700 illustrations. - 30 dessins anatomiques précisant les régions d'investigation.

Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.

Remarkable developments in the field of transplantation have created opportunities to address the formidable challenges of transplantation across histocompatibility barriers, stem cell expansion, and prevention of complications and generation of graft-vs-tumor activity to eradicate residual disease. Stem Cell Transplantation for Hematologic and Other Disorders, Second Edition provides a glimpse into potential future applications of bone marrow derived stem cells in the field of cardiac repair. The updated chapters introduce the biologic underpinnings of hematopoietic cell transplantation, basic stem cell biology, immunobiology, and histocompatibility, with emphasis on indications and results of transplantation for specific diseases. Written by experts in the field, Stem Cell Transplantation for Hematologic Disorders, Second Edition provides seasoned professionals with a complete understanding of the current state of transplantation biology as well as a clear vision into the future.

Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate differentiation, and immunomodulation. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas, and both basic and clinical scientists will benefit from this translational text.

Multiple drug resistance to antimicrobials is a growing problem that limits the effective lifetime of nearly all drugs developed against microorganisms. In Management of Multiple Drug-Resistant Infections, prominent clinicians and leading microbiologists describe how practicing physicians can best treat bacterial, viral, protozoal, and helminthic infections when there is significant resistance to antibiotics. The authors focus on the major hospital and community-acquired pathogens, including S. aureus, S. pneumoniae, Enterococcus, Acinetobacter, and M. tuberculosis, and on the management of such common problems as multiple drug-resistant urinary tract infections and gonorrhea. Among the resistant tropical organisms covered are Salmonella typhi, malaria, and Burkholderia pseudomalei. Resistance to such important antiviral classes as antiretrovirals and anticytomegaloviral agents is also discussed, as are those measures necessary to prevent the spread of infections among patients. When national or international treatment guidelines cannot be established, clinical trial data, in vitro susceptibility data, and epidemiologic and pharmacological evidence are cited to help make treatment decisions. Wherever possible, the question of drug resistance is set in the context of its biology and epidemiology. Comprehensive and practice-oriented, Management of Multiple Drug-Resistant Infections offers physicians and clinical microbiologists treating infectious disease patients not only a critically evaluated guide to the immense literature of the field, but also an up-to-date practical survey of today's gold-standard therapeutic strategies.

Extensively revised since the third edition in 1995, this comprehensive text covers all common and rare malignant blood cancers and is an essential reference for hematologists and oncologists. The sixty-two chapters are divided into sections on Chronic Leukemias and Related Disorders, Acute Leukemias, Myeloma and Related Disorders, Lymphomas, and Supportive Care.

There is no field of medicine in which advances in therapy have been so closely linked to a better understanding of molecular medicine than in the area of hematologic malignancies. Diagnostic and Therapeutic Advances in Hematologic Malignancies will provide practitioners and academic clinicians with a better understanding of the constantly evolving concepts in this area.